The US Medicare program’s Part D voluntary demonstration project focused on insulin costs is nearing launch with Trump administration fanfare and numerous insurers participating. But there is anticipation already that the approach might eventually expand to other drugs as well, and potentially other treatment areas.
Focused on insulin and insulin/drug combos, the demonstration project aims to cap copays at $35 for patients in different stages...